0000899243-20-011186.txt : 20200422 0000899243-20-011186.hdr.sgml : 20200422 20200422200040 ACCESSION NUMBER: 0000899243-20-011186 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200420 FILED AS OF DATE: 20200422 DATE AS OF CHANGE: 20200422 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GREEN JOHN B CENTRAL INDEX KEY: 0001243847 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 20808936 MAIL ADDRESS: STREET 1: C/O DICERNA PHARMACEUTICALS, INC. STREET 2: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205993609 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 33 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-04-20 0 0001399529 Dicerna Pharmaceuticals Inc DRNA 0001243847 GREEN JOHN B C/O DICERNA PHARMACEUTICALS, INC. 33 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Financial Officer Common Stock 2020-04-20 4 M 0 25624 5.45 A 45045 D Common Stock 2020-04-20 4 S 0 25624 22.95 D 19421 D Employee Stock Option (Right to Buy) 5.45 2020-04-20 4 M 0 25624 0.00 D 2026-04-14 Common Stock 25624 186375 D Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c). The reporting person sold an aggregate of 25,624 shares of common stock on April 20, 2020 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 4.01% of 638,583 shares of common stock, which is the number of shares of common stock owned by the reporting person prior to the Shares Sold transactions reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the reporting person as of the date of this report. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2019. As of the transaction date, the option was fully vested. The option vested 25% after the first year anniversary of the vesting start date of April 14, 2016 and the remaining 75% vested in 36 substantially equal monthly installments thereafter, subject in each case to the reporting person's continued service with the issuer through the applicable vesting date. /s/ John B. Green 2020-04-22